ArticleHeart (British Cardiac Society)2006
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy.
Article in Heart (British Cardiac Society), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03259113 (EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathy), which is not on this map. Cited by 92 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathy
Who cites it
92 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy.Circulation. Arrhythmia and electrophysiology · 2025Pooled it
- Guideline
- Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.The Cochrane database of systematic reviews · 2012Pooled it
- Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies.Journal of the American Heart Association · 2026Review
- Hypertrophic Cardiomyopathy and Risk of Out-of-Hospital Cardiac Arrest.JAMA network open · 2026Observational
- Long-term prognostic value of cardiopulmonary exercise testing in patients with hypertrophic cardiomyopathy.ESC heart failure · 2026Article
- The value of the transthoracic echocardiography score for screening significant coronary artery disease in patients with hypertrophic cardiomyopathy.Quantitative imaging in medicine and surgery · 2026Article
- A case of hypertrophic cardiomyopathy presenting with high-degree atrioventricular block.Medicine · 2025Article
- Cardiovascular comorbidities in hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate.Future cardiology · 2025Article
- Hypertrophic cardiomyopathy.Nature reviews. Disease primers · 2025Review
- Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities.Biomedicines · 2025Review
- Countywide burden, pathology, and genetics of lethal hypertrophic cardiomyopathy: from the POST SCD study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- An attractive alternative to prenatal diagnosis: a case report of preimplantation genetic testing in familial cardiomyopathy.AJOG global reports · 2025Article
- Non-sustained Ventricular Tachycardia and Hypertrophic Cardiomyopathy: When to Consider it as a Risk Factor for Sudden Death and Total Mortality?Arquivos brasileiros de cardiologia · 2025Article
- The Diagnosis and Treatment of Hypertrophic Cardiomyopathy.Deutsches Arzteblatt international · 2024Review
- Advances in Cardiac Imaging and Genetic Testing for Diagnosis and Risk Stratification in Cardiomyopathies: 2024 Update.Journal of clinical medicine · 2024Review
- Arrhythmogenesis in Fabry Disease.Current cardiology reports · 2024Review
- An Artificial Intelligence Analysis of Electrocardiograms for the Clinical Diagnosis of Cardiovascular Diseases: A Narrative Review.Journal of clinical medicine · 2024Review
- Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.Archivos de cardiologia de Mexico · 2024Article
- Arrhythmias and Hypertrophic Cardiomyopathy: Unravelling the Connection.Current cardiology reviews · 2024Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the range of survival rates of patients with hypertrophic cardiomyopathy (HCM) by comparing and contrasting the natural history of a cohort of patients seen between 1988 and 2002 with that of other published series.
methods956 adult (> or = 16 years old) patients with HCM (572 men, mean (SD) age 42 (15) years, range 16-88) were evaluated by ECG, Holter, exercise testing, and echocardiography. Patient characteristics and survival data were compared with those in natural history studies from referral and non-referral centres published between 1960 and January 2003.
resultsThe duration of follow up was 69 (45) months. 120 (12.6%) patients died or underwent cardiac transplantation. Sudden cardiac death (n = 48) was the most common mode of death. The annual rate of sudden death or implantable cardioverter-defibrillator discharge was 1.02 (95% confidence interval (CI) 0.76 to 1.26). Annual rates for heart failure death or transplantation and stroke related death were 0.55% (95% CI 0.37% to 0.78%) and 0.07% (95% CI 0.02% to 0.19%), respectively. When studies published within the last 10 years of the study period were compared with earlier reports, the size of individual study cohorts was larger (309 (240.6) v 136.5 (98.8), p = 0.058) and the proportion with severe functional limitation NYHA class III/IV lower (12.4% v 24.8%, p < 0.0001), and fewer patients underwent septal myotomy-myectomy (5.2% v 18.7%, p < 0.0001). Published sudden death rates over the last 10 years were lower than previously published figures (median 1.0% (range 0.1-1.7) v 2.0% (0-3.5)).
conclusionPublished survival rates in HCM cohorts have improved progressively over the past 40 years. In the modern era the prevalence of disease related complications is similar in all reporting centres.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.